COPD - Nationale VersorgungsLeitlinien

135. Watanabe S, Kanner RE, Cutillo AG, Menlove RL, Bachand RT, Jr., Szalkowski MB, Renzetti AD, Jr.
Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary
disease. Am Rev Respir Dis 1989;140(5):1269-73.
136. Bardsley PA, Howard P, DeBacker W, Vermeire P, Mairesse M, Ledent C, Radermecker M, Bury T,
Ansquer J. Two years treatment with almitrine bismesylate in patients with hypoxic chronic
obstructive airways disease. Eur Respir J 1991;4(3):308-10.
137. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine,
alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive
lung disease and normal blood gases. N Engl J Med 1981;305(27):1611-6.
138. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and
quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med
1998;157(6 Pt 1):1877-80.
139. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine
and promethazine on breathlessness and exercise tolerance in patients with chronic airflow
obstruction. Br J Dis Chest 1987;81(3):287-92.
140. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in
patients with chronic lung disease. Thorax 1989;44(5):387-90.
141. Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnoea and exercise
tolerance in the "pink puffer" syndrome. Eur Respir J 1991;4(8):926-31.
142. Schonhofer B, Suchi S, Haidl P, Köhler D. Eine Epidemiologie zum Stellenwert von oral appliziertem
Morphium als Therapieform des schwergradigen Lyngenemphysems vom Pink-Puffer-Type. Med
Klin (Munich) 2001;96(6):325-30.
143. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-
Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158(1):49-59.
144. Seersholm N,Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe
alpha 1-antitrypsin deficiency. Thorax 1998;53(4):265-8.
145. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin
deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche
Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur
Respir J 1998;11(2):428-33.
146. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective
assessment of home nebulizer treatment. Respir Med 1992;86(4):317-25.
147. Ram FS, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus
all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary
disease. Cochrane Database Syst Rev 2002;(1):CD002170.
148. Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC, Jr., Hudgel DW, Boyars MC, Sahn S.
Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med
1996;100(1A):62S-69.
149. Chavannes N, Vollenberg JJ, van Schayck CP, Wouters EF. Effects of physical activity in mild to
moderate COPD: a systematic review. Br J Gen Pract 2002;52(480):574-8.
150. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive
pulmonary disease stage. Am J Respir Crit Care Med 1999;160(4):1248-53.
151. Worth H, Meyer A, Folgering H, Kirsten D, Lecheler J, Magnussen H, Pleyer K, Schmidt S, Schmitz
M, Taube K, Wettengel R. Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen
Training bei Patienten mit obstruktiven Atemwegserkrankungen. Pneumologie 2000;54(2):61-7.
87
© 2006